Brain-derived neurotrophic factor, neurofilament light and glial fibrillary acidic protein do not change in response to aerobic training in people with MS-related fatigue - a secondary analysis of a randomized controlled trial

Mult Scler Relat Disord. 2023 Feb:70:104489. doi: 10.1016/j.msard.2022.104489. Epub 2022 Dec 28.

Abstract

Background: Neuroinflammation and neurodegeneration are pathological hallmarks of multiple sclerosis (MS). Brain-derived neurotrophic factor (BDNF), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) are blood-based biomarkers for neurogenesis, axonal damage and astrocyte reactivity, respectively. We hypothesize that exercise has a neuroprotective effect on MS reflected by normalization of BDNF, NfL and GFAP levels.

Objectives: To investigate the neuroprotective effect of aerobic training (AT) compared to a control intervention on blood-based biomarkers (i.e. BDNF, NfL, GFAP) in people with MS (pwMS).

Methods: In the TREFAMS-AT (Treating Fatigue in Multiple Sclerosis - Aerobic Training) study, 89 pwMS were randomly allocated to either a 16-week AT intervention or a control intervention (3 visits to a MS nurse). In this secondary analysis, blood-based biomarker concentrations were measured in 55 patients using Simoa technology. Changes in pre- and post-intervention concentrations were compared and between-group differences were assessed using analysis of covariance (ANCOVA). Confounding effects of age, sex, MS-related disability assessed using the Expanded Disability Status Scale (EDSS), MS duration, use of disease-modifying medication, and Body Mass Index were considered.

Results: Blood samples were available for 30 AT and 25 control group participants (mean age 45.6 years, 71% female, median disease duration 8 years, median EDSS score 2.5). Within-group changes in both study groups were small and non-significant, with the exception of BDNF in the control group (median (interquartile range) -2.1 (-4.7; 0)). No between-group differences were found for any biomarker: BDNF (β = 0.11, 95%CI (-3.78 to 4.00)), NfL (β = -0.04, 95%CI (-0.26 to 0.18)), and GFAP (β = -0.01, 95%CI (-0.16 to 0.15)), adjusted for confounders.

Conclusion: Aerobic exercise therapy did not result in statistically significant changes in the tested neuro-specific blood-based biomarkers in people with MS.

Trial registration: this study is registered under number ISRCTN69520623 (https://www.isrctn.com/ISRCTN695206).

Keywords: Brain-derived neurotrophic factor; Exercise; Glial fibrillary acidic protein; Multiple sclerosis; Neurofilament proteins; Neuroprotection.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Biomarkers
  • Brain-Derived Neurotrophic Factor
  • Female
  • Glial Fibrillary Acidic Protein
  • Humans
  • Intermediate Filaments / pathology
  • Male
  • Middle Aged
  • Multiple Sclerosis* / pathology
  • Neuroprotective Agents*

Substances

  • Biomarkers
  • Brain-Derived Neurotrophic Factor
  • Glial Fibrillary Acidic Protein
  • Neuroprotective Agents
  • BDNF protein, human
  • GFAP protein, human